Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust

被引:346
作者
Giesinger, Johannes M. [1 ]
Kieffer, Jacobien M. [1 ]
Fayers, Peter M. [2 ,3 ]
Groenvold, Mogens [4 ,5 ]
Petersen, Morten Aa. [4 ]
Scott, Neil W. [2 ]
Sprangers, Mirjam A. G. [6 ]
Velikova, Galina [7 ]
Aaronson, Neil K. [1 ]
机构
[1] Netherlands Canc Inst, Div Psychosocial Res & Epidemiol, NL-1066 CX Amsterdam, Netherlands
[2] Univ Aberdeen, Inst Appl Hlth Sci, Aberdeen AB25 2ZD, Scotland
[3] Norwegian Univ Sci & Technol, Fac Med, Dept Canc Res & Mol Med, N-7491 Trondheim, Norway
[4] Bispebjerg Hosp, Dept Palliat Med, Res Unit, DK-2400 Copenhagen, Denmark
[5] Univ Copenhagen, Dept Publ Hlth, DK-1014 Copenhagen, Denmark
[6] Univ Amsterdam, Acad Med Ctr, Dept Med Psychol, NL-1105 AZ Amsterdam, Netherlands
[7] Univ Leeds, St Jamess Inst Oncol, Leeds Inst Canc & Pathol, Leeds LS9 7TF, W Yorkshire, England
基金
奥地利科学基金会;
关键词
Health-related quality of life; Questionnaires; EORTC QLQ-C30; Measurement model; Higher order factor scores; Confirmatory factor analysis; QUALITY-OF-LIFE; GENERAL FACT-G; EUROPEAN-ORGANIZATION; FUNCTIONAL ASSESSMENT; ALTERNATIVE METHODS; CLINICAL-TRIALS; RELIABILITY; COUNTRIES; VARIABLES; THERAPY;
D O I
10.1016/j.jclinepi.2015.08.007
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objective: To further evaluate the higher order measurement structure of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30), with the aim of generating a summary score. Study Design and Setting: Using pretreatment QLQ-C30 data (N = 3,282), we conducted confirmatory factor analyses to test seven previously evaluated higher order models. We compared the summary score(s) derived from the best performing higher order model with the original QLQ-C30 scale scores, using tumor stage, performance status, and change over time (N = 244) as grouping variables. Results: Although all models showed acceptable fit, we continued in the interest of parsimony with known-groups validity and responsiveness analyses using a summary score derived from the single higher order factor model. The validity and responsiveness of this QLQ-C30 summary score was equal to, and in many cases superior to the original, underlying QLQ-C30 scale scores. Conclusion: Our results provide empirical support for a measurement model for the QLQ-C30 yielding a single summary score. The availability of this summary score can avoid problems with potential type I errors that arise because of multiple testing when making comparisons based on the 15 outcomes generated by this questionnaire and may reduce sample size requirements for health-related quality of life studies using the QLQ-C30 questionnaire when an overall summary score is a relevant primary outcome. (C) 2016 The Authors. Published by Elsevier Inc.
引用
收藏
页码:79 / 88
页数:10
相关论文
共 38 条
[1]   THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY [J].
AARONSON, NK ;
AHMEDZAI, S ;
BERGMAN, B ;
BULLINGER, M ;
CULL, A ;
DUEZ, NJ ;
FILIBERTI, A ;
FLECHTNER, H ;
FLEISHMAN, SB ;
DEHAES, JCJM ;
KAASA, S ;
KLEE, M ;
OSOBA, D ;
RAZAVI, D ;
ROFE, PB ;
SCHRAUB, S ;
SNEEUW, K ;
SULLIVAN, M ;
TAKEDA, F .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :365-376
[2]   Two kinds of items in quality of life instruments: 'Indicator and causal variables' in the EORTC QLQ-C30 [J].
Boehmer, S ;
Luszczynska, A .
QUALITY OF LIFE RESEARCH, 2006, 15 (01) :131-141
[3]   Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial [J].
Burris, Howard A., III ;
Lebrun, Fabienne ;
Rugo, Hope S. ;
Beck, J. Thaddeus ;
Piccart, Martine ;
Neven, Patrick ;
Baselga, Jose ;
Petrakova, Katarina ;
Hortobagyi, Gabriel N. ;
Komorowski, Anna ;
Chouinard, Edmond ;
Young, Robyn ;
Gnant, Michael ;
Pritchard, Kathleen I. ;
Bennett, Lee ;
Ricci, Jean-Francois ;
Bauly, Hounayda ;
Taran, Tetiana ;
Sahmoud, Tarek ;
Noguchi, Shinzaburo .
CANCER, 2013, 119 (10) :1908-1915
[4]   Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial [J].
Cella, D. ;
Pickard, A. S. ;
Duh, M. S. ;
Guerin, A. ;
Mishagina, N. ;
Antras, L. ;
Neary, M. P. ;
McCann, L. ;
Hodge, R. ;
Sternberg, C. N. .
EUROPEAN JOURNAL OF CANCER, 2012, 48 (03) :311-323
[5]   The Patient-Reported Outcomes Measurement Information System (PROMIS) Progress of an NIH roadmap cooperative group during its first two years [J].
Cella, David ;
Yount, Susan ;
Rothrock, Nan ;
Gershon, Richard ;
Cook, Karon ;
Reeve, Bryce ;
Ader, Deborah ;
Fries, James F. ;
Bruce, Bonnie ;
Rose, Mattias .
MEDICAL CARE, 2007, 45 (05) :S3-S11
[6]  
Cohen J, 2013, Statistical power analysis for the behavioral sciences, DOI [10.4324/9780203771587, DOI 10.4324/9780203771587]
[7]   Reliability and validity of the Functional Assessment of Cancer Therapy General (FACT-G) in French cancer patients [J].
Costet, N ;
Lapierre, V ;
Benhamou, E ;
Le Galès, C .
QUALITY OF LIFE RESEARCH, 2005, 14 (05) :1427-1432
[8]   Evaluation of the Functional Assessment of Cancer Therapy-General (FACT-G) Spanish Version 4 in South America: Classic Psychometric and Item Response Theory Analyses [J].
Juan J Dapueto ;
Carla Francolino ;
Liliana Servente ;
Chih-Hung Chang ;
Irene Gotta ;
Roberto Levin ;
María del Carmen Abreu .
Health and Quality of Life Outcomes, 1 (1)
[9]   Assessment of PRO Label Claims Granted by the FDA as Compared to the EMA (2006-2010) [J].
DeMuro, Carla ;
Clark, Marci ;
Doward, Lynda ;
Evans, Emily ;
Mordin, Margaret ;
Gnanasakthy, Ari .
VALUE IN HEALTH, 2013, 16 (08) :1150-1155
[10]  
Fayers P, 2002, EUR J CANCER, V38, pS125